IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages.
about
IL-33 signaling is essential to attenuate viral-induced encephalitis development by downregulating iNOS expression in the central nervous systemExtrinsic and intrinsic control of macrophage inflammatory responsesDealing with Danger in the CNS: The Response of the Immune System to Injury.Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathwayLimited anti-inflammatory role for interleukin-1 receptor like 1 (ST2) in the host response to murine postinfluenza pneumococcal pneumonia.The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malariaIL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis.Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.Role of IL-33 and its receptor in T cell-mediated autoimmune diseasesExpression of IL-33 and its epigenetic regulation in Multiple Sclerosis.IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells.Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis.Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotypeFasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis.Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil.IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells.Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.Inhibition of Spinal Interlukin-33/ST2 Signaling and Downstream ERK and JNK Pathways in Electroacupuncture Analgesia in Formalin Mice.IL-33 attenuates the development of experimental autoimmune uveitis.Cutting edge: c-Kit signaling differentially regulates type 2 innate lymphoid cell accumulation and susceptibility to central nervous system demyelination in male and female SJL miceIL-33 Aggravates DSS-Induced Acute Colitis in Mouse Colon Lamina Propria by Enhancing Th2 Cell ResponsesTLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin RepairInteraction of astrocytes and T cells in physiological and pathological conditionsElevated Circulating Interleukin 33 Levels in Stable Renal Transplant Recipients at High Risk for Cardiovascular Events.High salt reduces the activation of IL-4- and IL-13-stimulated macrophages.IL-1 family cytokines trigger sterile inflammatory disease.IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent.Implications for Interleukin-33 in solid organ transplantationGlia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases.The role of IL-33 in gut mucosal inflammation.Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system.TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses.Nitric oxide-induced regulatory T cells inhibit Th17 but not Th1 cell differentiation and function.Murine Cytomegalovirus Infection Induces Susceptibility to EAE in Resistant BALB/c Mice.IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.Cytokine control of inflammation and repair in the pathology of multiple sclerosis.Emerging role of interleukin-33 in autoimmune diseases.Effector and regulatory T cell subsets in diabetes-associated inflammation. Is there a connection with ST2/IL-33 axis? Perspective.
P2860
Q26700067-6955E2CA-51F2-4494-BBF0-18F64BF3D2A4Q26822651-245A9E77-51E4-4108-BC5C-2A349044533AQ30279070-EE245EF0-FF5C-4DFB-A175-4A112609EA03Q30724821-9ECAF538-E5BB-4AFB-BE7B-94D3188C6584Q31112685-786698D7-B848-415B-902F-093C4022A2CDQ33593742-7250BBA4-C3EF-4B3F-8FF8-F8107388C830Q33610655-A593B351-7B0F-4F25-8BA1-5DA75CE1D337Q33709412-B77BCB4B-7789-408F-8CBF-2C0573B394AFQ33768246-562D2624-6B5B-44F2-929E-F3EAE1B6F148Q33854499-369F206D-BE3B-44C8-AC1D-61B428103140Q34149191-1F74927F-8B69-4044-88E9-AE1F8C62300AQ34289318-0017929A-79CC-4022-830A-4B88C60B6A49Q34373132-7FF4A24A-4A14-475F-B9FF-BEBE15ECCEE7Q34428400-B0DE3B17-B5AD-47AA-AC20-F0C6E20C0B58Q34451923-3F7DF683-5D4C-459C-A8FD-800644B90861Q34589502-0FB4948A-E25D-4ACA-ABBD-E485F412C658Q35557167-23A429A0-93CA-46BB-9D9B-CF3479517F8CQ35590264-5F3C7B97-9CAD-4BFE-AD5B-7EAE71CDD89BQ35607302-AD230772-9340-4344-A0CF-0A553AE84232Q35661479-E5A79243-5481-42C7-AC0F-460EA4B4614CQ35665373-83B9451D-0A0D-4498-8C52-344D9552E3D5Q35691196-3E60CCF5-2375-4A87-A6F1-C62F36678EB3Q35730495-F73B3DCB-39CF-4B7D-A771-EC454988AC95Q35972372-E3170FDD-20E5-4225-997A-90115C06BB4EQ36058899-01436406-59E5-4F1C-A597-99CC7178A257Q36257484-2B419E43-D420-424A-82ED-AFBAB8F5112AQ36266456-0E7AD776-C943-4322-847D-712CCC2AFF59Q36304279-56400948-423B-4043-A719-4AADACD1C260Q36593464-7C3263AF-9DC6-44FD-846D-6366B33186ECQ36807908-2EA8A975-350F-4E34-BDE1-E4169F749C03Q36863846-77FE91B2-664E-4745-A440-89FAF6F5528EQ36914110-F946D982-C071-40D5-BA40-52C11E898A7EQ37126011-F6199FAD-9742-429B-BFA0-39F47B409DFBQ37169110-E7B77460-4DDC-4284-91D8-6DE1B9C04407Q37202357-B11518D2-42C8-4E6B-A08D-4514A2DD9AAAQ37667382-F294EEAE-4F0D-4849-B20E-2661564688E5Q37727601-39AF8899-F67D-4702-8093-63C06DDBDC82Q38067389-0117A2CB-6203-4964-AD03-C42D9CA0112DQ38151715-13DED099-8924-4459-A347-05A4CF21403BQ38189119-17C55EDF-AE40-4186-9F70-9B29FA57BA4D
P2860
IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
IL-33 attenuates EAE by suppre ...... atively activated macrophages.
@en
IL-33 attenuates EAE by suppre ...... atively activated macrophages.
@nl
type
label
IL-33 attenuates EAE by suppre ...... atively activated macrophages.
@en
IL-33 attenuates EAE by suppre ...... atively activated macrophages.
@nl
prefLabel
IL-33 attenuates EAE by suppre ...... atively activated macrophages.
@en
IL-33 attenuates EAE by suppre ...... atively activated macrophages.
@nl
P2093
P2860
P50
P356
P1476
IL-33 attenuates EAE by suppre ...... natively activated macrophages
@en
P2093
Anne-Galle Besnard
Debbie Allan
Hui-Rong Jiang
Jose C Alves-Filho
Marija Milovanović
Miodrag L Lukic
Wanda Niedbala
P2860
P304
P356
10.1002/EJI.201141947
P407
P577
2012-06-12T00:00:00Z